 Cocrystal Pharma Inc NASDAQ: COCP has announced laboratory-based results for its lead preclinical SARS-CoV-2 3CL protease inhibitor, CDI-45205. A third-party laboratory contracted by Cocrystal conducted in vitro studies evaluating the antiviral activity of CDI-45205 and its analogs in VeroE6-eGFP cells infected with SARS-CoV-2 Wuhan strain, the U.K. variant B.1.1.7, and the South African variant B.1.351. 